Business News • PR NewsWire • Halozyme's Ultrafast Insulin Accelerates Absorption and Lowers Hyperglycemia and Hypoglycemia Risk in Type 2 Diabetes Patients

Halozyme's Ultrafast Insulin Accelerates Absorption and Lowers Hyperglycemia and Hypoglycemia Risk in Type 2 Diabetes Patients

Halozyme's Ultrafast Insulin Accelerates Absorption and Lowers Hyperglycemia and Hypoglycemia Risk in Type 2 Diabetes Patients

SAN DIEGO, June 27 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced Phase 2 results demonstrating that the subcutaneous coinjection of rHuPH20 (recombinant human hyaluronidase, PH20) with lispro significantly improves postprandial hyperglycemia, reduces hypoglycem

View More : http://www.prnewswire.com/news-releases/halozymes-ultrafast-insulin-accelerates-absorption-and-lowers-hyperglycemia-and-...

Releted News by prnewswire

Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards

Industry Veteran Joins INKSURE Technologies Board

New Givex Uptix(TM) Ticket Technology Helps Teams Beat the Recession

Halozyme's Ultrafast Insulin Accelerates Absorption and Lowers Hyperglycemia and Hypoglycemia Risk in Type 2 Diabetes Patients

Rentrak Announces Official Box Office Totals for Weekend of June 25, 2010

Kerry Sullivan and Elise Schillmoller are the Male and Female Winners of the Fifth Annual Morton Plant Mease Triathlon